Cleavage of Bax-α and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line

Oral Oncology

Volumn 36, Issue 3, 2000, Pages 277-285

  Itoh, M ^a,b   Chiba, H ^a,b   Noutomi, T ^a,b   Takada, E ^b   Mizuguchi, J ^b  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bax; Bcl x(L); Carboplatin; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; CASPASE 3; CASPASE 8; DNA; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL X;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0034191968     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(00)00010-5     Document Type: Article

References (42)

1. Niitani H., Kobayashi K. Cisplatin/carboplatin therapy in non-small cell lung cancer. Oncology. 49(Suppl 1):1992;51-56.
2. Zamboglou N., Schnabel T., Kolotas C., Achterrath W., Strehl H., Dalhauser S., Vogt H.G., Lenaz L., Schmitt G. Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience. Seminars in Oncology. 21:1994;45-53.
3. Stiff P.J., McKenzie R.S., Alberts D.S., Sosman J.A., Dolan J.R., Rad N., McCloskey T. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. Journal of Clinical Oncology. 12:1994;176-183.
4. Zamble D.B., Lippard S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends in Biochemical Siences. 20:1995;435-439.
5. Barry M.A., Behnke C.A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthemia. Biochemical Pharmacology. 40:1990;2353-2562.
6. Felice V.D., Lauricella M., Giuliano M., Emanuele S., Vento R., Tesoriere G. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. International Journal of Oncology. 13:1998;225-232.
7. Chu G. Cellular responses to cisplatin: the roles of DNA-binding proteins and DNA repair. The Journal of Biological Chemistry. 269:1994;787-790.
8. Ormerod M.G., O'Neill C.F., Harrap K.R. Cisplatin induces apoptosis in a human ovarian caccinoma cell line without concomitant internucleosomal degradation of DNA. Experimental Cell Research. 211:1994;231-237.
9. Williams G.T., Smith C.A. Molecular regulation of apoptosis:genetic controls on cell death. Cell. 74:1993;777-779.
10. Schmitt C.A., Lowe S.W. Apoptosis and therapy. Journal of Pathology. 187:1999;127-137.
11. Susin S.A., Zamzami N., Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochemica et Biophysica ACTA. 1366:1998;151-165.
12. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
13. Deckwerth T.L., Johnson E.M. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. Journal of Cell Biology. 123:1993;1207-1222.
14. Marchetti P., Castedo M., Susin S.A., Zamzami N., Hirsch T., Macho A., Haeffner A., Hirsch F., Geuskens M., Kroemer G. Mitochondrial permeability transition is a central coordinating event of apoptosis. Journal of Experimental Medicine. 184:1996;1155-1160.
15. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., Susin S.A., Petit P.X., Mignotte B., Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. Journal of Experimental Medicine. 182:1995;367-377.
16. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:1997;479-489.
17. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
18. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M., Smulson M.E., Yamin T.-T., Yu V.L., Miller D.K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37-43.
19. Liu X., Zou H., Slaughter C., Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptsosis. Cell. 89:1997;175-184.
20. Chao D.T., Korsmeyer S.J. Bcl-2 family: regulators of cell death. Annual Review of Immunology. 16:1998;395-419.
21. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
22. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell. 74:1993;609-619.
23. Simonian P.L., Grillot D.A.M., Nunez G. Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death. Blood. 90:1997;1208-1216.
24. Cheng E.H.-Y, Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., Ueno K., Hardwick J.M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 278:1997;1966-1968.
25. L through caspase interaction. Proceedings of the National Academy of Science, USA. 95:1998;554-559.
26. Prime S.S., Nixon S.V., Crane I.J., Matthews A.S.J.B., Maitland N.J., Remnant L., Powell S.K., Game S.M., Scully C. The behaviour of human oral squamous cell carcinoma in cell culture. Journal of Pathology. 160:1990;259-269.
27. Yanase N., Takada E., Yoshihama I., Ikegami H., Mizuguchi J. Participation of Bax-α in IFN-α-mediated apoptosis in Daudi B lymphoma cells. Journal of Interferon and Cytokine Research. 18:1998;855-861.
28. Del Bino G., Skierski J.S., Darzynkiewicz Z. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells. Experimental Cell Research. 195:1991;485-491.
29. Salvesen G.S., Dixit V.M. Caspases: intracellular signaling by proteolysis. Cell. 91:1997;443-446.
30. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., Houtzager V.M., Nordstrom P.A., Roy S., Vaillancourt J.P., Chapman K.T., Nicholson D.W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. The Journal of Biological Chemistry. 272:1997;17 907-17 911.
31. Talanian R.V., Quinlan C., Trautz S., Hackett M.C., Mankovich J.A., Banach D., Ghayur T., Brady K.D., Wong W.W. Substrate specificities of caspase family proteases. The Journal of Biological Chemistry. 272:1997;9677-9682.
32. 2 phase and cell death induced by cisplatin. Journal of the National Cancer Institute. 82:1990;749-755.
33. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
34. Wesselborg S., Engels I.H., Rossmann E., Los M., Schulze-Osthoff K. Anticancer drug induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 9:1999;3053-3063.
35. Hirsch T., Marchetti P., Susin S.A., Dallaporta B., Zamzami N., Marzo I., Geuskens M., Kroemer G. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene. 15:1997;1573-1581.
36. Hengartner M.O. Death cycle and Swiss army knives. Nature. 391:1998;441-442.
37. Vercammen D., Brouckaert G., Denecker G., Craen M.V., Declercq W., Fiers W., Vandenabeele P. Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic death pathways. Journal of Experimental Medicine. 188:1998;919-930.
38. Nagai T., Yanase N., Mizuguchi J. Anti-CD40-mediated prevention of apoptosis of human germinal center B cells. The Journal of Tokyo Medical University. 56:1998;88-98.
39. Kobayashi T., Ruan S., Clodi K., Kliche K.-O., Shiku H., Andreeff M., Zhang W. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene. 16:1998;1587-1591.
40. Wood D.E., Thomas A., Devi L.A., Berman Y., Beavis R.C., Reed J.C., Newcomb E.W. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene. 17:1998;1069-1078.
41. Wood D.E., Newcomb E.W. Caspase-dependent activation of calpain during drug-induced apoptosis. The Journal of Biological Chemistry. 274:1999;8309-8315.
42. Schlesinger P.H., Gross A., Yin X.-M., Yamamoto K., Saito M., Waksman G., Korsmeyer S.J. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proceedings of the National Academy of Science, USA. 94:1997;11 357-11 362.